Zachary Boodoo - Graduate Student, Advisor: Meera Singh, PhD
As of 2021, approximately 38 million were living with HIV worldwide. The implementation and increased availability of combined antiretroviral therapy (cART) has both extended the lifespan and increased the quality of life for persons living with HIV (PLWH) while curtailing the rates of new infections (32% decline since 2010). These developments have made it possible for a significant population of HIV+ individuals to transition into middle and old age. Despite these advancements, PLWH exhibit an increased susceptibility to develop a vast number of comorbidities, which necessitates undertaking novel studies to address these concerns. One of these heightened disease states is cardiovascular disease, which is the subject of our research efforts.
Monocytes can be broadly classified into three subsets based on surface marker expression: classical (CD14+CD16-), intermediate (CD14+CD16+), and non-classical (CD14loCD16+). Although important in resolution of injury and homeostatic maintenance, non-classical monocytes, due to their pro-inflammatory phenotype, have been implicated in atherosclerosis (AS) by physically interacting with endothelial cells and contributing to plaque formation. Previous work done by our lab has demonstrated a higher percentage of these circulating non-classical monocytes in HIV+ individuals. Additionally, we observed a higher percentage of activated platelets in the same cohort, which have the propensity to form transient complexes with monocytes and induce their transition to the CD16+ subpopulation of interest. Platelet-monocyte complexes (PMCs) were found to be elevated in PLWH.
Platelets are the major source of circulating microparticles, which contain proteins, lipids, and RNA. Therefore, we hypothesize that platelet-monocyte complexes mediate efficient transfer of platelet-derived microparticles (PMPs), whose biomolecular contents induce monocyte maturation to the pro-inflammatory, CD16+ phenotype that is a major player in atherosclerosis and broader cardiovascular dysfunction. To investigate this, we will rely on human whole blood and plasma samples to isolate monocytes and platelet-derived microparticles, respectively, which were collected as part of a previously completed clinical study at the institution. Patients will be divided into subgroups based on HIV and AS status, with the latter determined by plaques revealed during carotid imaging data. Single-cell RNAseq and metabolic analysis will be performed on monocytes to construct a dynamic network model of gene expression that can identify differences in gene expression between patient groups. Concurrently, the miRNA and proteins enveloped within our isolated PMPs will be extracted and subject to small RNAseq and mass spectrometry analysis. miRNAs and proteins that differ between monocyte classes (platelet-complexed vs. non-complexed) or patient subgroups will be introduced into our network model to assess their ability to perturb monocytic signaling. Collectively, these sets of analyses will elucidate the impact of platelet-monocyte interactions on monocyte differentiation and function, and determine potential pathways that can be therapeutically targeted to prevent and treat AS.
As a preliminary experiment, platelet-derived microparticles were isolated from human plasma samples and incubated with both primary monocytes or U937 cells (a pro-monocytic cell line). Flow cytometry analysis demonstrated changes in cell surface marker expression between control and PMP-treated cells, however additional replicate experiments are needed to confirm these observations.
Feb 16, 2023 @ 12:00 p.m.
Medical Center | K-307 (306408)